Stockalyze
Example report. Sign up to run the same analysis on any ticker.
LEGN logoLEGNEquity research

Report date: 2026-06-03

$19.04-0.23 (-1.19%)Live · delayed quote, informational only

Analysis focus

Provide a balanced, comprehensive analysis: fundamentals and valuation, the Wall Street view, technical posture, and the key forward risks and catalysts.

Summary

Legend Biotech (NASDAQ: LEGN) is a commercial-stage cell-therapy company whose value is overwhelmingly tied to CARVYKTI (cilta-cel), a BCMA-directed CAR-T for multiple myeloma developed and co-commercialized 50/50 (ex-China) with Johnson & Johnson. The bull case rests on CARVYKTI's continued hypergrowth and an inflection to profitability: full-year 2025 net trade sales reached roughly $1.9 billion (Q4 2025 ~$555M, +66% YoY), and Q1 2026 net trade sales jumped ~62% YoY to ~$597M, driving Legend's reported revenue to ~$305M while the net loss narrowed sharply to ~$54.3M (adjusted net loss only ~$10.5M) from ~$101M a year earlier. The company holds ~$834.6M in cash plus deposits with no long-term debt, has reached CARVYKTI franchise profitability, guides to company-wide operating profit in 2026, and is expanding capacity (Raritan NJ build-out supporting up to ~10,000 patients/year; Ghent, Belgium production ramping in 1H 2026). Wall Street is broadly constructive: consensus is a 'Buy' with an average 12-month target near $55 (range roughly $27 to $86), and multiple firms raised targets after Q1 (UBS to $49, H.C. Wainwright to $65, RBC to $64), implying meaningful upside from the ~$34-36 share price (market cap ~$6.4-6.7B). The bear case centers on competition, manufacturing/supply complexity, partner economics, and geopolitics. Off-the-shelf BCMA bispecifics (J&J's own Tecvayli, Pfizer's Elrexfio) offer ready-to-use convenience versus the slow, complex autologous CAR-T process, and rival CAR-T anito-cel (Gilead/Arcellx) claims a differentiated safety profile, though analyst models still project CARVYKTI (~$6.3B by 2032) far ahead of anito-cel (~$658M). Manufacturing capacity has historically capped CARVYKTI's uptake, making the Ghent/Raritan ramp a critical execution risk. Because Legend shares CARVYKTI profits equally with J&J ex-China, its economics depend on a single partnered asset, and the pipeline beyond cilta-cel (LB2102/DLL3 with Novartis, LB2501) is early-stage. Finally, Legend's China heritage and former GenScript majority ownership expose it to BIOSECURE-Act-style political risk; Legend removed GenScript as majority shareholder and has explored an Asian secondary listing to mitigate this. Note: at least one tracker (stockinvest.us) showed an implausible ~42% one-day spike on June 2, 2026 that other sources do not corroborate (stockanalysis.com showed ~$34.50, down ~5% on June 3), so very-short-term price prints should be treated with caution.

Findings (14)

As of early June 2026, LEGN traded around $34.50 with a market capitalization of roughly $6.4 billion (stockinvest.us showed ~$36.28 / $6.71B on June 2).

High confidence

stockanalysis.com listed $34.50 and a $6.41B market cap on June 3, 2026; stockinvest.us listed $36.28 and $6.71B as of June 2, 2026.

stockanalysis.comstockinvest.us

LEGN's 52-week range is approximately $16.24 (low) to $45.30 (high).

High confidence

Both trackers independently report a 52-week low near $16.24 and a high of $45.30.

stockanalysis.comstockinvest.us

Q1 2026 CARVYKTI net trade sales were approximately $597 million, up ~62% year-over-year, with ex-US sales up ~222%.

High confidence

Multiple summaries of Legend's Q1 2026 6-K earnings release cite ~$597M net trade sales, +62% YoY, with a 222% jump outside the US.

stocktitan.netgrafa.comsec.gov

Legend's Q1 2026 total revenue was ~$305.1 million (including ~$298.4M CARVYKTI collaboration revenue), and net loss narrowed to ~$54.3 million from ~$101 million a year earlier (adjusted net loss ~$10.5M vs ~$27.0M).

High confidence

Earnings coverage of the Q1 2026 6-K reports $305.1M revenue, a narrowed $54.3M net loss, and a $10.5M adjusted net loss.

tipranks.comstocktitan.net

Legend ended Q1 2026 with ~$834.6 million in cash plus deposits and no long-term debt; Q1 R&D expense was ~$86 million and gross margin on net product sales was ~41% (guided to exceed 50% next quarter).

High confidence

Q1 2026 earnings summaries cite $834.6M cash+deposits, no long-term debt, ~$86M R&D, and 41% gross margin with a >50% next-quarter outlook.

stocktitan.netfinance.yahoo.com

Full-year 2025 CARVYKTI net trade sales reached approximately $1.9 billion, with Q4 2025 at ~$555 million (+66% YoY, +6% sequential), and the CARVYKTI franchise achieved profitability.

High confidence

Q4/FY2025 results (reported March 10, 2026) show ~$555M Q4 sales and ~$1.9B full-year sales, with franchise profitability achieved.

investing.comstocktitan.net

2025 quarterly CARVYKTI sales rose steadily: ~$369M (Q1), ~$439M (Q2), ~$524M (Q3), ~$555M (Q4).

High confidence

Legend's 2025 quarterly 6-K filings and Q4 coverage report the sequential quarterly progression.

sec.govinvesting.com

Analyst consensus on LEGN is 'Buy' with an average 12-month price target around $55.39 and a range of roughly $27 (low) to $86 (high).

High confidence

stockanalysis.com cites 15 analysts (S&P Global) with a Buy consensus, $55.39 average target, and a $27-$86 range; MarketBeat shows a similar Buy skew.

stockanalysis.commarketbeat.com

Multiple analysts raised price targets after Q1 2026: UBS to $49 (from $31) on June 3, H.C. Wainwright to $65 (from $50) on June 1, and RBC's Leonid Timashev to $64 (from $62) on May 13, 2026, all keeping bullish ratings.

High confidence

stockanalysis.com forecast page lists the UBS, H.C. Wainwright and RBC target increases with dates following Q1 results.

stockanalysis.combenzinga.com

CARVYKTI manufacturing capacity is expanding: the Raritan, NJ facility build-out (described as the largest US cell-therapy plant) supports up to ~10,000 patients/year, and the Ghent, Belgium (Tech Lane) site received EU approval and begins supporting global demand in 1H 2026.

High confidence

Legend's JPM 2026 business update and BioSpace report describe the Raritan ~10,000-patient capacity and Ghent commercial production ramp.

investors.legendbiotech.combiospace.com

CARVYKTI faces competition from off-the-shelf BCMA bispecifics (J&J's Tecvayli, Pfizer's Elrexfio) that offer ready-to-use dosing versus complex autologous CAR-T manufacturing.

High confidence

Industry coverage positions Tecvayli and Elrexfio as convenient ready-to-use alternatives to CAR-T, with Elrexfio offering an every-other-week maintenance schedule.

biopharmadive.comfiercepharma.com

Rival CAR-T anito-cel (Gilead/Arcellx) claims differentiated safety, but analyst models project anito-cel sales of only ~$658 million by 2032 versus ~$6.3 billion for CARVYKTI across eight major markets.

Medium confidence

Clinical Trials Arena cites the ~$658M (anito-cel) vs ~$6.3B (CARVYKTI) 2032 projections; these are third-party analyst forecasts, not company guidance.

clinicaltrialsarena.combiospace.com

Legend carries BIOSECURE-Act-style geopolitical risk tied to its China operations and former GenScript majority ownership; GenScript was removed as majority shareholder and Legend has explored an Asian secondary listing to mitigate the risk.

Medium confidence

Fierce Pharma reports the GenScript majority-shareholder removal, congressional scrutiny of GenScript/Legend China ties, and BIOSECURE-Act exposure.

fiercepharma.comfiercepharma.com

Legend was the subject of takeover/M&A speculation (with J&J floated as a potential buyer and Centerview retained as adviser), though the most recent confirmed reports date to 2024 rather than 2026.

Medium confidence

BioProcess International and Fierce Pharma reported a 2024 takeover bid and adviser hire; no verified 2026 acquisition announcement was found.

bioprocessintl.comfiercepharma.com

Sources (21)

Caveats

Data is time-sensitive as of 2026-06-03; biotech prices move sharply on data readouts and M&A headlines. There is a notable price-data discrepancy: stockinvest.us reported a ~42% one-day spike to $36.28 on June 2, 2026, which other sources (stockanalysis.com, ~$34.50, down ~5% on June 3) do not corroborate, suggesting a data anomaly rather than a confirmed catalyst — treat very-short-term price prints with low confidence. The takeover/M&A speculation is sourced to 2024 reports, not a verified 2026 event. Primary SEC 6-K filings were not all directly fetchable, so several Q1 2026 and FY2025 financials rely on secondary summaries (StockTitan, TipRanks, Investing.com) that are consistent with each other but not independently re-keyed from the filing text. Peak-sales figures ($6.3B CARVYKTI / $658M anito-cel by 2032) are third-party analyst projections, not company guidance, and carry model risk. With ~$835M cash and no long-term debt, enterprise value is roughly equal to or modestly below market cap (~$6B). No buy/sell/hold recommendation is given.

This report is for informational purposes only and is not investment advice. No buy / sell / hold recommendation is made or implied.

Want this on your watchlist?

Add your own focus, pick a delivery speed, and get a source-verified report like this one.